BALAXI PHARMACEUTICALS LIMITED

rs,

d Compliance Officer) Membership No.: F11744 Encl: A/a Registered Office: 2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-Ill , Hyderabad, Telangana , India - 500096. CIN:L25

400 billion

icaragua _......, Ecuador ~ Chile Balaxi Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9 e Existing Markets • Targeted Expansion •Product Sourcing

6 billion

le Balaxi Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9 e Existing Markets • Targeted Expansion •Product Sourcing Regions _j ________ I I I

INR 49.36 Crore

manufacturing facility Successfully completed fund raising exercise through Preferential Issue – INR 49.36 Crore 10 Balaxi _j _______ _ I I I I I I I Corporate Structure Balaxi Pharmaceuticals Limi

Rs. 50 crore

egulatory submissions across the board. Moreover, following the successful preferential issue of ~ Rs. 50 crore, we are well-positioned to commission our EU GMP manufacturing facility by March 2024. Driving thi

23%

n is a substantial asset that will create long-term, sustainable value for all our stakeholders.” 23% Revenues 88% Gross Profit 5% EBITDA 28% Profit After Tax 46% Return on Equity Debt Free Ashi

88%

tial asset that will create long-term, sustainable value for all our stakeholders.” 23% Revenues 88% Gross Profit 5% EBITDA 28% Profit After Tax 46% Return on Equity Debt Free Ashish Maheshwari

5%

ll create long-term, sustainable value for all our stakeholders.” 23% Revenues 88% Gross Profit 5% EBITDA 28% Profit After Tax 46% Return on Equity Debt Free Ashish Maheshwari Chairman & Manag

28%

long-term, sustainable value for all our stakeholders.” 23% Revenues 88% Gross Profit 5% EBITDA 28% Profit After Tax 46% Return on Equity Debt Free Ashish Maheshwari Chairman & Managing Director

46%

value for all our stakeholders.” 23% Revenues 88% Gross Profit 5% EBITDA 28% Profit After Tax 46% Return on Equity Debt Free Ashish Maheshwari Chairman & Managing Director Balaxi 15 _j ____

41.7%

% EBITDA EBITDA Margin % Profit After Tax PAT Margin % Earnings Per Share (INR) 86.38 36.05 41.7% 14.75 17.1% 15.49 17.9% 15.49 70.23 19.16 27.3% 14.03 20.0% 12.05 17.2% 12.05 YoY +2

17.1%

TDA Margin % Profit After Tax PAT Margin % Earnings Per Share (INR) 86.38 36.05 41.7% 14.75 17.1% 15.49 17.9% 15.49 70.23 19.16 27.3% 14.03 20.0% 12.05 17.2% 12.05 YoY +23.0% +88.1%

“Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.”

“Going forward, we see several levers that will potentially add value to the operations over the next several years – geographical expansion into new frontier markets, leverage of existing competencies to gain scale in additional geographies, deep market penetration in previously launched operations and a very strong pipeline of product registrations and regulatory submissions across the board.”

“Driving this initiative forward, we completed land acquisition previously, a leading consultant has been appointed for project execution and the ground breaking ceremony is scheduled on December 12, 2022.”

Registered Office

1

Established operations

1

Expansion initiated

1

Registered Office

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-Ill , Hyderabad, Telangana , India - 500096. CIN:L25191TG1942PLC121598 Phone: +91 40 23555300 I Email: info@balaxi.in I Website: www.balaxipharma.in Balax i Pharmaceuticals Limited Branded IPR-driven Pharma Player in Frontier Markets Q2 FY23 Financial Results _j _______ _ I Disclaimer • • • Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Balaxi Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. Balaxi 2 _j

Established operations

Guatemala (Latin America), Dominican Republic (Caribbean) and Angola (Africa) New operations: Honduras and El Salvador

Expansion initiated

Nicaragua, Ecuador, Chile (Latin America) Central African Republic, Zambia (Africa) Products Vast range of essential OTC medicines – with healthy mix of generics and branded generics 745 product registrations in six countries 646 new registrations submitted or in the pipeline Supply Chain Outsourced production from WHO GMP certified plants in India, China and Portugal Establishing EU GMP compliant facilities in Hyderabad Distribution Deep presence through 37 warehouses and on-ground fleet support Transformation Balaxi New initiatives strengthening functionality in supply chain, regulatory affairs and customer service Successful process being replicated in other frontier markets; expansion plans in other global markets over near to medium term Centralized digital procurement, regulatory management and customized CRM tools 5 __j _______ _ I I I I I I I Key Success Factors Market Selection Methodology  Focus on countries with high-potential economic growth framework  Identify non-Englis